Hypothesis

Combined pharmacological NLRP3 inhibition (e.g., MCC950), IL-6 receptor blockade (e.g., anti‑IL‑6R antibody), and periodic senolytic clearance (e.g., dasatinib + quercetin) will reverse age‑associated immunosenescence in humans by reducing inflammasome‑driven oxidative stress in hematopoietic stem cells (HSCs), thereby restoring youthful DNA methylation patterns and lymphoid‑myeloid balance.

Mechanistic Rationale

NLRP3 activation in aged macrophages and perivascular adipose tissue releases caspase‑1‑processed IL-1β and IL-18, which augment mitochondrial ROS production in neighboring HSCs [1][3]. Elevated ROS drives DNMT3A‑mediated hypermethylation at promoters of lymphoid‑specification genes (e.g., IKZF1, EBF1), biasing hematopoiesis toward myeloid output and exacerbating inflammaging [4]. IL-6, while not a direct NLRP3 product, amplifies STAT3 signaling that further stabilizes the senescent phenotype in macrophages and impairs HSC niche support [2]. Senolytics eliminate NLRP3‑primed senescent immune cells, decreasing the chronic cytokine milieu that sustains HSC stress [5]. Simultaneous NLRP3 blockade cuts the upstream ROS source, IL-6 inhibition dampens the downstream amplifier, and senolytic removal reduces the cellular source of inflammasome activators, together normalizing the oxidative‑epigenetic axis in HSCs.

Testable Predictions

1. In a double‑blind, placebo‑controlled trial of adults aged 65‑80, participants receiving the triple regimen for 12 months will show a ≥20 % increase in the lymphoid‑to‑myeloid ratio in peripheral blood compared with baseline and with single‑agent arms.
2. Epigenetic clocks (e.g., GrimAge) applied to sorted CD34⁺ HSCs will demonstrate a reversal of ≥1.5 years in biological age after treatment, whereas monotherapy groups will show ≤0.5 year change.
3. Ex vivo LPS‑stimulated macrophages from treated donors will produce TNF‑α and IL‑1β at levels not significantly different from those of young adult controls (≤15 % variance), confirming functional rescue beyond cytokine normalization.
4. MRI‑based perivascular adipose tissue inflammation (measured by T1‑rho mapping) will decrease by ≥30 % only in the triple‑therapy group, linking vascular improvement to immunologic reversal.

Falsifiability

If after 12 months the triple regimen fails to produce a statistically significant improvement in any of the primary endpoints (lymphoid‑to‑myeloid ratio, HSC epigenetic age, macrophage cytokine profile, or perivascular adipose inflammation) relative to placebo, the hypothesis that combined NLRP3/IL‑6/senolytic intervention reverses immunosenescence is falsified. Additionally, observation of worsened cytopenias or increased infection rates would contradict the predicted restorative effect.